• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Inhibition of CHK1 and WEE1 as a new therapeutic approach in diffuse large B cell lymphomas with MYC deregulation.

作者信息

Restelli Valentina, Vagni Micaela, Arribas Alberto J, Bertoni Francesco, Damia Giovanna, Carrassa Laura

机构信息

Laboratory of Molecular Pharmacology, Department of Oncology, IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy.

Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland.

出版信息

Br J Haematol. 2018 Apr;181(1):129-133. doi: 10.1111/bjh.14506. Epub 2016 Dec 26.

DOI:10.1111/bjh.14506
PMID:28025833
Abstract
摘要

相似文献

1
Inhibition of CHK1 and WEE1 as a new therapeutic approach in diffuse large B cell lymphomas with MYC deregulation.抑制CHK1和WEE1作为MYC失调的弥漫性大B细胞淋巴瘤的一种新治疗方法。
Br J Haematol. 2018 Apr;181(1):129-133. doi: 10.1111/bjh.14506. Epub 2016 Dec 26.
2
Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading.由于细胞周期蛋白依赖性激酶（CDK）活性和CDC45装载的不同调节，联合抑制Wee1和Chk1在S期可产生协同性DNA损伤。
Oncotarget. 2017 Feb 14;8(7):10966-10979. doi: 10.18632/oncotarget.14089.
3
Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.联合抑制Chk1和Wee1作为套细胞淋巴瘤的一种新治疗策略。
Oncotarget. 2015 Feb 20;6(5):3394-408. doi: 10.18632/oncotarget.2583.
4
Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.LIM蛋白AJUBA的突变介导头颈部鳞状细胞癌对细胞周期抑制剂治疗的敏感性。
Cancer Lett. 2017 Apr 28;392:71-82. doi: 10.1016/j.canlet.2017.01.024. Epub 2017 Jan 23.
5
Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.对一种对Chk1抑制剂PF-00477736耐药的套细胞淋巴瘤细胞系的鉴定
Oncotarget. 2015 Nov 10;6(35):37229-40. doi: 10.18632/oncotarget.5954.
6
Pharmacological targeting the ATR-CHK1-WEE1 axis involves balancing cell growth stimulation and apoptosis.对ATR-CHK1-WEE1轴进行药理学靶向涉及平衡细胞生长刺激和细胞凋亡。
Oncotarget. 2014 Nov 15;5(21):10546-57. doi: 10.18632/oncotarget.2508.
7
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma.DNA损伤反应通路的组成性激活作为弥漫性大B细胞淋巴瘤的新型治疗靶点
Oncotarget. 2015 Mar 30;6(9):6553-69. doi: 10.18632/oncotarget.2720.
8
Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.通过抑制 WEE1 诱导 S 期细胞强制有丝分裂进入作为一种治疗策略。
Cancer Discov. 2012 Jun;2(6):524-39. doi: 10.1158/2159-8290.CD-11-0320. Epub 2012 Apr 23.
9
Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress.ATR 和 WEE1 抑制剂在与复制应激相关的高度敏感的弥漫性大 B 细胞淋巴瘤亚群中的差异活性。
Cancer Res. 2019 Jul 15;79(14):3762-3775. doi: 10.1158/0008-5472.CAN-18-2480. Epub 2019 May 23.
10
Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.联合抑制 Chk1 和 Wee1：体外协同作用转化为体内肿瘤生长抑制。
Cell Cycle. 2012 Jul 1;11(13):2507-17. doi: 10.4161/cc.20899.

引用本文的文献

1
Synthetic Lethal Combinations of DNA Repair Inhibitors and Genotoxic Agents to Target High-Risk Diffuse Large B Cell Lymphoma.DNA修复抑制剂与基因毒性药物的合成致死组合靶向高危弥漫性大B细胞淋巴瘤
Hematol Oncol. 2025 Sep;43(5):e70131. doi: 10.1002/hon.70131.
2
Multi-omics and experimental validation reveal mechanism of compound mylabris capsules in treating diffuse large B-cell lymphoma.多组学与实验验证揭示复方斑蝥胶囊治疗弥漫性大B细胞淋巴瘤的机制
Sci Rep. 2025 Jul 4;15(1):23856. doi: 10.1038/s41598-025-09767-5.
3
Targeting the DNA damage response in cancer.
靶向癌症中的DNA损伤反应。
MedComm (2020). 2024 Oct 31;5(11):e788. doi: 10.1002/mco2.788. eCollection 2024 Nov.
4
Targeting the DNA damage response in hematological malignancies.针对血液系统恶性肿瘤中的DNA损伤反应
Front Oncol. 2024 Jan 29;14:1307839. doi: 10.3389/fonc.2024.1307839. eCollection 2024.
5
Combined inhibition of Wee1 and Chk1 as a therapeutic strategy in multiple myeloma.联合抑制Wee1和Chk1作为多发性骨髓瘤的一种治疗策略。
Front Oncol. 2023 Dec 6;13:1271847. doi: 10.3389/fonc.2023.1271847. eCollection 2023.
6
DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities.癌症治疗与耐药中的 DNA 损伤反应：挑战与机遇。
Int J Mol Sci. 2022 Nov 24;23(23):14672. doi: 10.3390/ijms232314672.
7
Stable Knock-Out Ovarian Cancer Cells Do Not Show Increased Sensitivity to Cisplatin and PARP Inhibitor Treatment.稳定敲除的卵巢癌细胞对顺铂和PARP抑制剂治疗未表现出敏感性增加。
Front Oncol. 2022 Jul 13;12:903536. doi: 10.3389/fonc.2022.903536. eCollection 2022.
8
A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target.WEE1 家族企业：调控有丝分裂、癌症进展和治疗靶标。
J Hematol Oncol. 2020 Sep 21;13(1):126. doi: 10.1186/s13045-020-00959-2.
9
Multi-Platform Omics Analysis for Identification of Molecular Characteristics and Therapeutic Targets of Uveal Melanoma.多平台组学分析鉴定葡萄膜黑色素瘤的分子特征和治疗靶点。
Sci Rep. 2019 Dec 17;9(1):19235. doi: 10.1038/s41598-019-55513-z.
10
Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia.通过抑制WEE1和CHK1在急性淋巴细胞白血病中产生协同作用
Cancers (Basel). 2019 Oct 25;11(11):1654. doi: 10.3390/cancers11111654.